Axcess Global Sciences v. TruBrain: Ketone Supplement Patent Dispute Settles in 154 Days
Axcess Global Sciences (AGS) asserted six patents covering exogenous ketone and ketogenic precursor supplement formulations against TriplePulse, Inc. doing business as TruBrain in Delaware District Court. The parties reached a confidential settlement, with AGS filing a voluntary dismissal with prejudice under Rule 41(a)(1)(A)(i) — just 154 days after filing, and before any answer or summary judgment motion was served.
Six-Patent Ketone IP Dispute Ends in Pre-Answer Settlement
On June 6, 2025, Axcess Global Sciences, LLC filed suit against TriplePulse, Inc. (dba TruBrain) in the District of Delaware, asserting infringement of six U.S. patents — US10596131B2, US10588876B2, US11020362B2, US10292952B2, US11241403B2, and US10736861B2 — each directed to exogenous ketones and ketogenic precursor supplement products. AGS is represented by Potter Anderson & Corroon, LLP, a prominent Delaware IP firm, suggesting deliberate forum selection in a court well-versed in patent disputes.
The case closed on November 7, 2025, when AGS filed a notice of voluntary dismissal with prejudice pursuant to Rule 41(a)(1)(A)(i), citing an executed settlement agreement. Critically, no answer or motion for summary judgment had been filed before dismissal, meaning the settlement was reached entirely at the pre-answer stage. The parties jointly requested the court retain jurisdiction to enforce the settlement agreement, a standard protective mechanism that preserves judicial oversight of compliance.
A resolution in 154 days — before any substantive court filings by the defendant — suggests either an early licensing agreement or a swift commercial resolution once litigation pressure was applied. The settlement terms are confidential, so it is unknown whether TruBrain obtained a license, agreed to reformulate, or paid a lump sum. The with-prejudice dismissal means AGS cannot re-file the same claims against TruBrain on the same patents, making the settlement’s scope commercially significant even if undisclosed.
Filing to Voluntary dismissal in 154 days
154 days — resolved well before the typical 2–3 year district court patent trial timeline
Settled and dismissed with prejudice: what the resolution means for both parties
Rule 41(a)(1)(A)(i) dismissal with prejudice explained
A Rule 41(a)(1)(A)(i) notice may be filed by a plaintiff without court approval before the defendant serves an answer or a summary judgment motion. Filing it ‘with prejudice’ — as AGS did here — is a voluntary but permanent relinquishment: AGS cannot re-sue TruBrain on these six patents for the same accused products. This is the standard mechanism used to close out a settled patent dispute while making the dismissal binding on the plaintiff.
Permanent bar on re-filingAGS extracts a confidential settlement before incurring full litigation costs
AGS achieved a resolution before spending significant resources on discovery or claim construction. The confidential settlement likely includes financial consideration and/or a licence, consistent with AGS’s apparent role as an IP licensing entity. The with-prejudice dismissal signals AGS received satisfactory terms — patent holders rarely concede a permanent bar without commercial compensation. AGS retains its six patents and can continue enforcing them against other market participants.
Settlement secured pre-answerTruBrain resolves dispute early — but settlement terms remain confidential
TriplePulse / TruBrain avoided a full patent trial and the attendant reputational and financial exposure. No defendant counsel appears on the public record, which may indicate the company negotiated directly or retained counsel not yet entered in the docket. The settlement terms are undisclosed, so whether TruBrain obtained a licence, paid a royalty, or modified its products is unknown from the public record. The court’s retained jurisdiction to enforce the agreement adds ongoing legal accountability.
Terms undisclosedSix-patent portfolio signals aggressive ketone supplement IP enforcement
The breadth of AGS’s asserted portfolio — six patents spanning multiple application numbers — suggests a systematic IP position in the exogenous ketone and ketogenic precursor space. Other supplement brands commercialising similar formulations should treat this settlement as a signal that AGS is actively licensing and enforcing its portfolio. The pre-answer settlement also demonstrates that litigation threat alone can drive resolution, lowering AGS’s enforcement cost per case.
Broad portfolio enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axcess Global Sciences, LLC | Company | Exogenous ketone supplement IP licensor — holder of US10596131B2 and 5 related patentsSearch in Eureka ↗ |
| Defendant | TriplePulse, Inc. | Company | TriplePulse, Inc. dba TruBrain — direct-to-consumer ketogenic and nootropic supplement brandSearch in Eureka ↗ |
| Plaintiff counsel | Andrew Mark Moshos | Attorney | Counsel for Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Bindu Ann George Palapura | Attorney | Counsel for Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Plaintiff counsel | David Ellis Moore | Attorney | Counsel for Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Potter Anderson & Corroon, LLP | Law Firm | Representing Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice confirms that settlement — not judicial determination — drove the outcome. The with-prejudice designation is the operative legal fact: it extinguishes AGS’s ability to re-assert these six patents against TruBrain for the accused products, functioning as a binding resolution equivalent to a final judgment on the merits for preclusion purposes. The absence of any defendant filing and the joint jurisdiction-retention request together indicate the parties reached agreement quickly and on terms both sides accepted without court intervention.
US10596131B2 and five related AGS ketone supplement patents
The six asserted patents — US10596131B2, US10588876B2, US11020362B2, US10292952B2, US11241403B2, and US10736861B2 — share application filing dates ranging from 2017 to 2021, spanning a period of rapid commercial growth in the ketogenic diet supplement market. The patents collectively cover exogenous ketones and ketogenic precursor formulations, a technology domain encompassing compounds such as beta-hydroxybutyrate (BHB) salts and esters used as dietary supplements to elevate blood ketone levels without strict dietary restriction.
This portfolio’s breadth across multiple application families suggests AGS has deliberately built layered protection across composition, method, and potentially dosage-form claims — making design-around strategies non-trivial for competitors. As the ketone supplement market has expanded into mainstream sports nutrition, cognitive performance, and metabolic health segments, IP enforcement activity in this space is intensifying. Any brand commercialising BHB-based or ketogenic precursor products should treat AGS’s portfolio as a primary FTO consideration, given the demonstrated willingness to litigate against direct-to-consumer supplement companies.
Should your ketone supplement product be cleared against AGS’s patent portfolio?
If your company markets exogenous ketone products, BHB salts, ketone esters, or ketogenic precursor supplements — including sports nutrition, weight management, or cognitive-performance formulations — the AGS patent portfolio is directly relevant to your freedom-to-operate position. This case confirms AGS is actively enforcing its rights against commercial supplement brands, and the portfolio spans at least six issued U.S. patents across multiple application families filed between 2017 and 2021.
PatSnap Eureka’s FTO Search Agent enables your R&D and legal teams to systematically map each AGS patent’s independent claims against your product’s composition, process, and intended use — identifying whether any claim reads on your formulation and surfacing prior art or design-around opportunities. Running an FTO before product launch or a new market entry is substantially less costly than defending a Delaware patent action, even one that settles quickly.
Run a freedom-to-operate analysis on US10596131B2 to assess your product’s exposure
Run FTO in Eureka →Similar ketone supplement patent infringement cases in U.S. district courts
Cases involving exogenous ketone and dietary supplement patent enforcement in U.S. district courts — particularly Delaware — provide essential benchmarking context for AGS’s litigation strategy.
What this case signals for the ketone supplement IP landscape
A six-patent assertion resolved in five months points to a maturing and increasingly contested IP environment in the functional supplement sector.
Pre-answer settlement suggests AGS’s portfolio carries credible infringement risk
TruBrain settled before filing any substantive response, which typically signals either strong patent coverage or commercially rational cost-avoidance. For competitors in the exogenous ketone space, this outcome reinforces that AGS’s portfolio warrants serious FTO analysis before product launch or reformulation.
Court’s retained jurisdiction creates an ongoing compliance obligation for TruBrain
AGS and TruBrain jointly requested the Delaware court retain jurisdiction to enforce the settlement. This is not boilerplate — it means any breach of the settlement agreement can be resolved through court order rather than fresh litigation, giving AGS an expedited enforcement pathway if TruBrain deviates from agreed terms.
Axcess v TriplePulse — key questions answered
AGS asserted six U.S. patents: US10596131B2, US10588876B2, US11020362B2, US10292952B2, US11241403B2, and US10736861B2. All relate to exogenous ketone and ketogenic precursor supplement formulations. The case was filed in the District of Delaware on June 6, 2025.
The case was resolved by a confidential settlement agreement. AGS filed a voluntary dismissal with prejudice under Rule 41(a)(1)(A)(i) on November 7, 2025 — 154 days after filing. No answer or summary judgment motion had been filed by the defendant. The parties jointly requested the court retain jurisdiction to enforce the settlement.
A dismissal with prejudice permanently bars AGS from re-filing the same patent infringement claims against TruBrain for the accused exogenous ketone products. It does not limit AGS’s ability to enforce those patents against other third parties. For TruBrain, it effectively ends the dispute on those specific claims, subject to any licensing terms in the confidential settlement.
Delaware is a strategically popular venue for patent infringement suits given its experienced judiciary and well-developed patent case law. AGS is represented by Potter Anderson & Corroon, LLP — a leading Delaware IP firm — suggesting intentional forum selection. The court’s familiarity with complex patent disputes may have influenced the choice, and defendants incorporated in Delaware are subject to personal jurisdiction there.
Companies marketing BHB-based, ketone ester, or ketogenic precursor supplements should conduct a freedom-to-operate analysis against AGS’s six-patent portfolio before commercialising new products. The pre-answer settlement in this case suggests AGS’s patents carry sufficient credibility to prompt early resolution. Monitoring AGS’s enforcement activity and any new patent applications in this family is also advisable for ongoing IP risk management.
PatSnap Eureka searches patents and litigation data to answer instantly.